Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.

被引：0

作者：

Reck, Martin

Lee, Ki Hyeong

Frost, Nicolaj

Breder, Valeriy Vladimirovich

Kowalski, Dariusz

Levchenko, Evgeny

Reguart, Noemi

Martinez-Marti, Alex

Houghton, Baerin

Paoli, Jean-Baptiste

Safina, Sufiia

Komiya, Takefumi

Sanford, Amy

Liu, Hong

Song, Andrew J.

Keller, Steven M.

Jabbour, Salma K.

机构：

[1] Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany

[2] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[3] Charit Univ Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Berlin Inst Hlth, Berlin, Germany

[7] N N Blokhin Russian Canc Res Ctr, Moscow, Russia

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[9] N N Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia

[10] Hosp Clin Barcelona, Dept Med Oncol, Thorac Oncol Unit, IDIBAPS, Barcelona, Spain

[11] Vall Hebron Inst Oncol VHIO, Hosp Univ Vall Hebron, Barcelona, Spain

[12] Mid North Coast Canc Inst, Port Macquarie Base Hosp, Port Macquarie, NSW, Australia

[13] Clin Clairval, Radiotherapie, Marseille, France

[14] Republican Dispensary Tatarstan MoH, Med Oncol, Kazan, Russia

[15] Sunny Buffalo, Div Hematol Oncol, Buffalo, NY USA

[16] Sanford Hlth, Sioux Falls, SD USA

[17] Merck Co Inc, Kenilworth, NJ USA

[18] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8508

引用

页数：1

共 35 条

[1] Pembrolizumab plus Concurrent Chemoradiation Therapy (cCRT) for Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 2-Year Update
Jabbour, S. K.
Lee, K. H.
Frost, N.
Breder, V.
Kowalski, D.
Levchenko, E.
Reguart, N.
Martinez-Marti, A.
Houghton, B.
Paoli, J. B.
Safina, S.
Komiya, T.
Sanford, A.
Liu, H.
Song, A. J.
Keller, S.
Reck, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S29 - S30
[2] Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
Reck, M.
Lee, K. H.
Frost, N.
Kowalski, D. M.
Breder, V.
Pollock, T.
Reguart, N.
Houghton, B.
Quantin, X.
Keller, S. M.
Liu, H.
Piperdi, B.
Jabbour, S. K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S103 - S104
[3] Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799
Jabbour, S. K.
Lee, K. H.
Frost, N.
Breder, V.
Kowalski, D.
Alawin, I.
Levchenko, E.
Reguart, N.
Martinez-Marti, A.
Houghton, B.
Paoli, J. B.
Safina, S.
Park, K.
Komiya, T.
Sanford, A.
Boolell, V.
Liu, H.
Samkari, A.
Keller, S.
Reck, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S9 - S10
[4] KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Breder, Valeriy Vladimirovich
Kowalski, Dariusz M.
Alawin, Issam Abdelkarim
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufia
Park, Keunchil
Komiya, Takefumi
Sanford, Amy
Boolell, Vishal
Liu, Hong
Samkari, Ayman
Keller, Steven M.
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non-small-cell lung cancer (NSCLC): From KEYNOTE-799
Reck, Martin
Lee, Ki Hyeong
Frost, Nikolaj
Breder, Valeriy Vladimirovich
Kowalski, Dariusz M.
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufiia
Liu, Hong
Novinskiy, Vladimir
Dettman, E. J.
Kobie, Julie
Jabbour, Salma K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer The Phase 2 KEYNOTE-799 Nonrandomized Trial
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nikolaj
Breder, Valeriy
Kowalski, Dariusz M.
Pollock, Theodore
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufia
Park, Keunchil
Komiya, Takefumi
Sanford, Amy
Boolell, Vishal
Liu, Hong
Samkari, Ayman
Keller, Steven M.
Reck, Martin
JAMA ONCOLOGY, 2021, 7 (09) : 1351 - 1359
[7] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Kowalski, Dariusz
Breder, Valeriy Vladimirovich
Pollock, Theodore
Reguart, Noemi
Houghton, Baerin
Quantin, Xavier
Keller, Steven M.
Liu, Hong
Piperdi, Bilal
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012
Jabbour, S.
Cho, B. C.
Bria, E.
Kato, T.
Bhosle, J.
Gainor, J. F.
Reguart, N.
Wang, L.
Morgensztern, D.
Gurary, E. B.
Ashraf, T. B.
Lara-Guerra, H.
Reck, M.
ANNALS OF ONCOLOGY, 2020, 31 : S810 - S811
[9] KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non-Small-Cell Lung Cancer
Jabbour, S. K.
Cho, B. C.
Bria, E.
Kato, T.
Bhosle, J.
Gainor, J. F.
Reguart, N.
Wang, L.
Morgensztern, D.
Gurary, E. B.
Ashraf, T. B.
Lara-Guerra, H.
Reck, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E440 - E441
[10] Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
Jabbour, Salma K.
Cho, Byoung Chul
Bria, Emilio
Kato, Terufumi
Bhosle, Jaishree
Gainor, Justin F.
Reguart, Noemi
Wang, Luhua
Morgensztern, Daniel
Gurary, Ellen
Ashraf, Tanya B.
Lara-Guerra, Humberto
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 →